AXIOMPHARMACEUTICALS
Peptide Database

Tissue repair & recovery

Tri-Heal Max Protocol (Tri-Heal Max)

High-Dose Three-Peptide Healing Blend

Overview

Tri-Heal Max is an enhanced healing peptide blend featuring a higher dose of TB-500 (25mg) combined with BPC-157 (10mg) and KPV (10mg) for a total of 45mg per vial. This formulation emphasizes TB-500's tissue repair and cellular migration properties, complemented by BPC-157's growth factor upregulation and KPV's anti-inflammatory effects. The higher TB-500 ratio (2.5:1:1) compared to standard healing stacks targets more significant tissue damage or accelerated recovery needs.

Each peptide contributes distinct healing pathways: TB-500 (Thymosin Beta-4) enhances cellular migration, promotes actin polymerization, and supports blood vessel formation for tissue repair; BPC-157 upregulates growth factors (VEGF, EGF), accelerates wound healing, and provides gastrointestinal protection; KPV (alpha-MSH fragment) inhibits the NF-κB inflammatory pathway, reduces pro-inflammatory cytokines, and may improve injection site tolerability. Together, they address inflammation, tissue regeneration, and cellular repair.

Higher TB-500 dose targets more severe tissue damage requiring enhanced repair.

TB-500 promotes muscle fiber repair and cellular migration.

Combined collagen support and growth factor upregulation.

Multi-modal support for surgical wound recovery.

Mechanism

Tri-Heal Max is an enhanced healing peptide blend featuring a higher dose of TB-500 (25mg) combined with BPC-157 (10mg) and KPV (10mg) for a total of 45mg per vial. This formulation emphasizes TB-500's tissue repair and cellular migration properties, complemented by BPC-157's growth factor upregulation and KPV's anti-inflammatory effects. The higher TB-500 ratio (2.5:1:1) compared to standard healing stacks targets more significant tissue damage or accelerated recovery needs.

Each peptide contributes distinct healing pathways: TB-500 (Thymosin Beta-4) enhances cellular migration, promotes actin polymerization, and supports blood vessel formation for tissue repair; BPC-157 upregulates growth factors (VEGF, EGF), accelerates wound healing, and provides gastrointestinal protection; KPV (alpha-MSH fragment) inhibits the NF-κB inflammatory pathway, reduces pro-inflammatory cytokines, and may improve injection site tolerability. Together, they address inflammation, tissue regeneration, and cellular repair.

Higher TB-500 dose targets more severe tissue damage requiring enhanced repair.

Research areas

  • Tri-Heal Max is an enhanced healing peptide blend featuring a higher dose of TB-500 (25mg) combined with BPC-157 (10mg) and KPV (10mg) for a total of 45mg per vial. This formulation emphasizes TB-500's tissue repair and cellular migration properties, complemented by BPC-157's growth factor upregulation and KPV's anti-inflammatory effects. The higher TB-500 ratio (2.5:1:1) compared to standard healing stacks targets more significant tissue damage or accelerated recovery needs.
  • Each peptide contributes distinct healing pathways: TB-500 (Thymosin Beta-4) enhances cellular migration, promotes actin polymerization, and supports blood vessel formation for tissue repair; BPC-157 upregulates growth factors (VEGF, EGF), accelerates wound healing, and provides gastrointestinal protection; KPV (alpha-MSH fragment) inhibits the NF-κB inflammatory pathway, reduces pro-inflammatory cytokines, and may improve injection site tolerability. Together, they address inflammation, tissue regeneration, and cellular repair.
  • Higher TB-500 dose targets more severe tissue damage requiring enhanced repair.
  • TB-500 promotes muscle fiber repair and cellular migration.
  • Combined collagen support and growth factor upregulation.
  • Multi-modal support for surgical wound recovery.
  • KPV component reduces post-surgical inflammatory response.
  • Enhanced tissue remodeling may reduce scar formation.
  • Accelerated return to activity after sports injuries.
  • Address accumulated tissue damage from repetitive stress.

Research notes

  • Injection site reactions (KPV may help reduce these)
  • Mild fatigue during healing
  • Temporary redness at injection site
  • Severe injection site reactions or signs of infection
  • Allergic reactions (rash, swelling, difficulty breathing)
  • Unusual bleeding or bruising
  • Worsening of underlying conditions
  • No clinical trials on this three-peptide combination
  • Active cancer (theoretical concern with growth-promoting peptides)
  • Pregnancy or breastfeeding
  • Active infection at injection site

FAQs

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, major surgery recovery, or chronic tissue damage requiring enhanced regenerative support beyond standard healing stacks.

Is KPV necessary in Tri-Heal Max or is it just TB-500 and BPC-157?

KPV adds anti-inflammatory effects by inhibiting the NF-κB pathway and reducing pro-inflammatory cytokines, complementing TB-500's cell migration and BPC-157's growth factor upregulation. KPV may also reduce injection site reactions, making the three-peptide blend more tolerable than two-peptide combinations.

How long should someone use Tri-Heal Max and can it be cycled indefinitely?

Standard protocol is 4-6 weeks of active healing, then 2-4 weeks off to assess tissue recovery. Cycling prevents tolerance and allows natural healing processes to consolidate gains. Long-term indefinite use isn't studied - rotate on/off cycles or reduce to maintenance (1-2x weekly) after acute phase resolves.

Can Tri-Heal Max be used for cosmetic healing (scars, skin texture) or just injury recovery?

Tri-Heal Max's multi-modal healing could theoretically support scar reduction and skin quality improvement through enhanced collagen remodeling and angiogenesis. However, clinical data is limited to musculoskeletal injuries - cosmetic use is experimental and requires realistic expectations about scar improvement potential.